Regulatory Affairs and Clinical Development Organisation intending to help progress the development of the new generation of therapeutic products
Joined July 2019
- Tweets45
- Following40
- Followers35
- Likes35
Rapid growth puts Australian CRO Accelagen on the map for clinical research globally - PR Newswire APAC en.prnasia.com/releases/apac…
We’ve been working on something exciting in the background, and are proud to finally start to introduce Accelagen’s new look with you.
linkedin.com/feed/update/urn…
I’m supporting @AusBiotech's #AusBio21 conference online and on-demand from 25 - 29
October - will you be attending? Register today & I look forward to seeing you online
ausbiotechnc.org/register202…
To learn a more about who Accelagen are and what we do - check out this short video
youtu.be/ZV74nzNiJFs
More exciting news from the Accelagen team! We are excited to partner with RemeGen to progress the development of their novel antibody-drug conjugate in Australia.
Read about it here linkedin.com/feed/update/urn…
Accelagen are proud of a collaboration that provide new treatment options for Australian patients, particularly for those who suffer from rare diseases.
Read more here: linkedin.com/feed/update/urn…
#regulatoryaffairs #regulatoryapproval #strategicpathtomarket
Unfortunately with #viclockdown, the team can't attend @ARCSAustralia Conference. However our Regulatory Manager Sarah Henderson will be there - meet up with her to discuss how the Accelagen team can drive your objectives!
#regulatoryaffairs #ARCS2021 #strategicpathtomarket
Check out the Accelagen profile on the Victorian Clinical Trials gateway here: victrials.com.au/partners/ac…. Although our head office is in Victoria, our team are based around Australia, ensuring we can remain active during #VicLockdown
#clinicaltrials #regulatoryaffairs
Great to be featured in the BioMelbourne Network newsletter!
Get in touch and discover more about the team and what we do to make a difference!
linkedin.com/posts/accelagen…
Proud to be supporting the development of new diagnostic technology that will aid in improving the diagnosis of colorectal cancer
$RHY continues to position itself as a global leader in colorectal cancer diagnosis, through the development of ColoSTAT®.
Half-Year report highlights:
↗️ Core Technology
↗️ Global Capability
↗️ Commercialisation
#bowelcancer #cancer
Link to report: bit.ly/3sqr0dK
Our clinical and regulatory teams continue to expand! An opportunity to contribute to the development of some cool new technologies. Watch this space for more job ads coming out!!
#clinicalresearch #regulatoryaffairs #joinin #newtechnologies #strategicpathtomarket
We are on the look out for an Office Manager who is seeking a fun, dynamic and fulfilling role within our growing Company.
Check out this job on SEEK: seek.com.au/job/51456113?sha…
#officemanager #contribute #team #clinicalresearch #regulatoryaffairs
A major milestone!
The TGA has granted provisional approval to Pfizer Australia Pty Ltd for its COVID-19 vaccine, COMIRNATY, making it the first COVID-19 vaccine to receive regulatory approval in Australia.
Read more: tga.gov.au/media-release/tga…
SureClinical Supports Accelagen COVID-19 Phase 2 Trial with Complimentary Access to SureClinical Platform marketwatch.com/press-releas…
A great initiative for Sponsors to interact with @TGAgovau early. Get in touch with us if interested in accessing this service
Today we launched the Early Scientific Advice service, a new initiative enabling applicants to request scientific advice on specific data before they apply to register a medicine. To access the Early Scientific Advice service or find out more visit: tga.gov.au/publication/early…
The @TGAgovau have introduced Early Scientific Advice program to allow Sponsors to discuss specific data and gain Agency feedback prior submitting application for product registration. A great initiative!
#regulatoryaffairs #scientificadvice linkedin.com/posts/accelagen…
Accelagen Pty Ltd retweeted
No one knows what the effectiveness of a Covid vaccine will be—we don’t have the studies yet. But even very good vaccines don’t take most diseases off the table. It’s going to take a comprehensive response, working together, to get past this.
It has been a busy time for our regulatory team, with the submission of four Cat 1’s to the TGA and an IND Amendment this week. Our regulatory publishing activities have certainly gone up a gear.
#ectd #regulatoryaffairs #lorenz #newproducts
Accelagen Pty Ltd retweeted
#ICYMI: at the start of this month, @nucleus_network begun dosing for its third #COVID19 vaccine trial in Melbourne! They are partnered w local sponsor @accelagen & they have been amazed by the public enthusiasm to volunteer for the trial nucleusnetwork.com/news/nucl…